Page 3 - ம+una+னா லானி வளைகுடா ஹோட்டல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ம+una+னா லானி வளைகுடா ஹோட்டல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ம+una+னா லானி வளைகுடா ஹோட்டல் Today - Breaking & Trending Today

Mauna Kea Technologies to Announce 2020 Full Year Results and Q1 2021 Sales on April 22, 2021 After Market Closes


Mauna Kea Technologies to Announce 2020 Full Year Results and Q1 2021 Sales on April 22, 2021 After Market Closes
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio
, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, announced today that it will publish its financial results for 2020 and Q1 2020 sales
on Thursday, April 22, 2021, at 5:45 PM CEST (Paris time).
An English-language conference call will be held at 6:00 PM CEST, Paris time (12 noon, New York time), to review the financial results, recent operational accomplishments, 2021 outlook and answer questions
To access the conference call, please use one of the following dial-in numbers at least 5 minutes prior to the scheduled start time: ....

New York , United States , France General , United Kingdom , Thomas Grojean , Mauna Kea , Mike Piccinino , Kea Technologies , Cap Investor Relations , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ஒன்றுபட்டது கிஂக்டம் , ம Una னா கீ , கீ தொழில்நுட்பங்கள் , தொப்பி முதலீட்டாளர் உறவுகள் ,

Mauna Kea Technologies Supports Clinical Research Evaluating the Use of Cellvizio on COVID-19 Patients with Respiratory Insufficiency


Mauna Kea Technologies Supports Clinical Research Evaluating the Use of Cellvizio on COVID-19 Patients with Respiratory Insufficiency
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is supporting research to determine if Cellvizio can be effective in severe acute and/or long COVID-19 patients suffering from lingering respiratory complications. Mauna Kea Technologies is offering in-kind funding to researchers evaluating what role Cellvizio may play in the care management of COVID-19 patients, by assessing lung fibrosis and microvascularization changes, and alveolar and capillary morphology damages; symptoms observed in severe acute and/or long COVID-19 patients with mild to severe respiratory infections. Interested clinical teams can submit their projects to this website: www.landing.maunakeatech.com/covid19. ....

United States , France General , Noord Holland , Robertl Gershon , Jouket Annema , Marcus Schultz , Lieuwe Bos , Thomas Grojean , Olesyav Danilevskaya , Jouke Annema , Kirstena Mooij Kalverda , Mike Piccinino , Peter Bonta , Research Clinical Center , Malanip Health Consequences , French Financial Markets Authority Autorit , Amsterdam University Medical Center , Measure Acute , Long Term Pulmonary , Kea Technologies , Chief Executive Officer , Mauna Kea , Pulmonary Endoscopy , Netherlands Trial Registry , Professor Annema , Federal Research Clinical Center ,